Company Directory

Company Directory

Company Directory - Argenx

Company Details - Argenx

Argenx Logo

Argenx

Website

Belgium (Ghent), Belgium

NASDAQ: ARGX 

ISIN: NL0011375019

Argenx is a biotechnology company focused on developing innovative therapies for patients with severe autoimmune diseases and cancer. The company employs a unique approach that harnesses the power of the immune system to discover and develop therapeutic antibodies.

CCI Score

CCI Score: Argenx

79.03

-0.04%

Latest Event

argenx 2023 Annual Report: Strong Commitment to Ethical and Social Responsibility

The 2023 Argenx Annual Report details comprehensive non-financial disclosures that highlight robust adherence to ethical practices, strong labor and human rights standards, anti-discrimination and anti-corruption measures, and firm environmental compliance. No material breaches were reported, demonstrating a progressive commitment to social responsibility and a resistance to authoritarian practices.

Take Action

So what can you do? Support Argenx by shopping, spreading the word, or offering your support.

Use Your Voice
OTHER TOOLS
Investigate
Share the Score
SUPPORT CCI

LEADER

Argenx is currently rated as a Leader.

+45 to +100 CCI Score
Companies in this range actively lead the fight against authoritarianism by rejecting oppressive practices and championing democratic values. They implement robust policies, engage in transparent governance, and drive initiatives that set the standard for corporate responsibility.

Latest Events

  • argenx 2023 Annual Report: Strong Commitment to Ethical and Social Responsibility Logo
    DEC
    31
    2023

    The 2023 Argenx Annual Report details comprehensive non-financial disclosures that highlight robust adherence to ethical practices, strong labor and human rights standards, anti-discrimination and anti-corruption measures, and firm environmental compliance. No material breaches were reported, demonstrating a progressive commitment to social responsibility and a resistance to authoritarian practices.

  • +90

    Labor Relations and Human Rights Practices

    October 10

    argenx's report emphasizes a strong culture of compliance and ethical behavior. The detailed disclosure concerning labor rights, human rights, diversity, and anti-corruption measures—with no identified breaches—indicates a proactive stance against authoritarian and exploitative practices, aligning well with progressive, anti-fascist values.

    argenx Annual Report 2023

Corporate Financials

Revenue
2024
$100.00M
Total Assets
2024
$800.00M
Operating Income
2024
-$50.00M
Total Equity
2024
$300.00M

Employees: 500

Industries

325412
Pharmaceutical Preparation Manufacturing
621511
Medical Laboratories
541711
Research and Development in Biotechnology